share_log

Helen Of Troy Analyst Ratings

Benzinga ·  Oct 5, 2023 14:23
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/05/2023 34.88% Canaccord Genuity $155 → $143 Maintains Buy
07/12/2023 49.97% DA Davidson $138 → $159 Maintains Buy
07/11/2023 46.2% Canaccord Genuity $130 → $155 Maintains Buy
04/27/2023 30.16% DA Davidson → $138 Reiterates → Buy
04/17/2023 -6.62% UBS → $99 Initiates Coverage On → Neutral
03/10/2023 30.16% DA Davidson → $138 Reiterates → Buy
01/06/2023 30.16% DA Davidson $126 → $138 Maintains Buy
01/03/2023 22.62% Canaccord Genuity $120 → $130 Maintains Buy
12/22/2022 18.85% DA Davidson $115 → $126 Upgrades Neutral → Buy
11/17/2022 13.19% Canaccord Genuity → $120 Initiates Coverage On → Buy
10/06/2022 8.47% DA Davidson $175 → $115 Maintains Neutral
07/13/2022 Raymond James Initiates Coverage On → Market Perform
07/08/2022 65.06% DA Davidson $244 → $175 Maintains Neutral
05/02/2022 130.15% DA Davidson $251 → $244 Maintains Neutral
04/28/2022 136.75% DA Davidson $255 → $251 Maintains Neutral
02/07/2022 148.07% Sidoti & Co. → $263 Upgrades Neutral → Buy
01/07/2022 140.52% DA Davidson $266 → $255 Maintains Neutral
12/01/2021 150.9% DA Davidson $254 → $266 Maintains Neutral
10/08/2021 139.58% DA Davidson $223 → $254 Maintains Neutral
04/14/2021 110.34% DA Davidson $247 → $223 Maintains Neutral
03/17/2021 132.97% DA Davidson $260 → $247 Downgrades Buy → Neutral
01/28/2021 Oppenheimer Downgrades Outperform → Perform
01/08/2021 121.66% B of A Securities → $235 Downgrades Buy → Neutral
01/08/2021 145.24% DA Davidson $246 → $260 Maintains Buy
10/09/2020 132.03% DA Davidson $243 → $246 Maintains Buy
09/02/2020 129.2% DA Davidson $237 → $243 Reiterates → Buy
07/10/2020 123.54% DA Davidson $197 → $237 Maintains Buy
04/30/2020 74.5% Oppenheimer $175 → $185 Maintains Outperform
04/30/2020 79.21% B of A Securities $160 → $190 Reiterates → Buy
04/29/2020 85.81% DA Davidson $196 → $197 Maintains Buy
04/08/2020 65.06% Oppenheimer $210 → $175 Maintains Outperform
03/31/2020 84.87% DA Davidson $227 → $196 Reiterates → Buy
02/06/2020 98.08% Oppenheimer → $210 Initiates Coverage On → Outperform
12/20/2019 79.21% B of A Securities $175 → $190 Reiterates → Buy
10/09/2019 65.06% B of A Securities $170 → $175 Maintains Buy
10/07/2019 73.55% DA Davidson $172 → $184 Maintains Buy
08/19/2019 62.23% DA Davidson $167 → $172 Maintains Buy
07/10/2019 55.63% B of A Securities $160 → $165 Reiterates → Buy
05/22/2019 50.91% B of A Securities $135 → $160 Maintains Buy
05/08/2019 Sidoti & Co. Downgrades Buy → Neutral

What is the target price for Helen Of Troy (HELE)?

The latest price target for Helen Of Troy (NASDAQ: HELE) was reported by Canaccord Genuity on October 5, 2023. The analyst firm set a price target for $143.00 expecting HELE to rise to within 12 months (a possible 34.88% upside). 11 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Helen Of Troy (HELE)?

The latest analyst rating for Helen Of Troy (NASDAQ: HELE) was provided by Canaccord Genuity, and Helen Of Troy maintained their buy rating.

When is the next analyst rating going to be posted or updated for Helen Of Troy (HELE)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Helen Of Troy, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Helen Of Troy was filed on October 5, 2023 so you should expect the next rating to be made available sometime around October 5, 2024.

Is the Analyst Rating Helen Of Troy (HELE) correct?

While ratings are subjective and will change, the latest Helen Of Troy (HELE) rating was a maintained with a price target of $155.00 to $143.00. The current price Helen Of Troy (HELE) is trading at is $106.02, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment